Cefixime and clavulanic acid

[dut]

Hi - my dd had a wonderful PANDAS symptom response to augmentin a couple of years ago but on day 8 started a serious serum sickness reaction and can no longer take penicillins.

 

It was the first time we had tried augmentin and hadn't had the same PANDAS improvement with penicillins prior to this and thought it might be the clavulanic acid that led to the improvement. Clavulanic acid is being researched as an anxiolytic.

 

I have read that a cepholosporin and clavulanate combination is available but from what I can see, it isn't available in the US.

 

Any experience with this?

 

Thanks

Edited August 7, 2012 by dut

[MomWithOCDSon]

Dut --

 

Been watching your post with interest, hoping someone would pipe in here with some info for you. Best I can tell, this drug combination is available in India but not very many other places?!?! That's crazy.

 

Do you work with an integrative, DAN! or LLMD at all? If so, would one of them just provide you a script for the clavulanic acid and you could pick that up at a compounding pharmacy? I've read some of the research pertaining to clav acid, also, and I do think there's something to it.

 

Sorry I'm of no real help, but wishing you luck!

[dut]

Hi Momwith....

 

I remember trying to find clav on its own a couple of years ago but will try again. We know a cool, compounding pharmacist that knows his stuff. I'll ask him. When I looked at it a while back there was a drug company (rexahn, I believe) that was doing either 1 or 2nd stage trials of a drug mainly consisting of clav for neurodegenerative and psych disorders but it was still in the early stages. I'll go see where that has got to as well, if I can find any info.

 

I'll post whatever I find out. Maybe a holiday in India is in order. The kids love Indian food

 

I'm grasping around for straws 'cos my soon to be kindergarten ds has been in a minor flare for 3-4 weeks and his only remaining symptom is fairly debilitating separation anxiety. He won't even stay with my dh. Any other time I'd just ride it out but with school starting in 4 weeks I'm panicking a bit......

[dut]

Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin

October 3rd, 2011

 

 

 

Study sheds light on Serdaxin as an enhancer of dopamine and serotonin release (SERDA); Novel mechanism may be able to address both negative mood and loss of positive mood in depressed patients

 

Rockville, Md., October 3, 2011 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a peer reviewed study in Neuroscience Letters that validates the mechanism of action of clavulanic acid, the active compound in Serdaxin®, the company’s lead CNS drug currently in Phase II clinical development for major depressive disorder.

 

The published study, “Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking,” shows that clavulanic acid enhances release of neurotransmitters such as dopamine in the brain cell by interacting with key proteins for vesicle trafficking and fusion.

 

“This study is significant because it confirms at the molecular and cellular levels how Serdaxin enhances the release of neurotransmitters in the brain. Previous studies demonstrated the release of serotonin and dopamine in the brain by clavulanic acid in live animals. These results strongly support that Serdaxin’s CNS effects may be due to an enhanced release of the dual neurotransmitters, called as the SERDA mechanism.” said Dr. Chang Ahn, Chairman and CEO of Rexahn.

 

Dr. Ahn elaborated, “Because the effectiveness of currently marketed therapies that modulate serotonin reuptake is significantly limited, there exists very strong therapeutic needs for depression patients who are non-responders, are relapsed, or are non-compliant due to adverse reactions of those therapeutics. Serdaxin positions itself to address these therapeutic and safety needs as the first SERDA antidepressant with excellent safety profile.”

 

Dr. Michael Thase, Chairman of the Depression Scientific Advisory Board of Rexahn, said, “This study illustrates that clavulanic acid may have important effects on monoaminergic neurotransmission, that are the result of interaction with vesicle trafficking and fusion through a novel mechanism involving Munc18 and Rab proteins. Enhancing the release of both dopamine and serotonin to physiological levels in the brain may prove to have novel therapeutic implications for those who suffer from major depressive disorder and other neurological disorders.”

[dut]

Clavulanic acid inhibits MPP(+)-induced ROS generation and subsequent loss of dopaminergic cells.

 

Kost GC, Selvaraj S, Lee YB, Kim DJ, Ahn CH, Singh BB.

 

 

Source

 

Rexahn Pharmaceuticals, Inc., Rockville, MD 20850, United States.

 

 

Abstract

 

Clavulanic acid is a psychoactive compound that has been shown to modulate central nervous system activity. Importantly, in neurotoxin-induced animal models, clavulanic acid has been shown to improve motor function (Huh et al., 2010) suggesting that it can be neuroprotective; however, the mechanism as how clavulanic acid can induce neuroprotection is not known. We demonstrate here that clavulanic acid abrogates the effects of the neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) which mimics Parkinson's disease (PD) by inducing neurodegeneration. To further establish the mechanism we identified that clavulanic acid inhibits neurotoxin-induced loss of mitochondrial membrane potential and ROS production. Consistent with these results, neurotoxin-induced increase in Bax levels was also decreased in clavulanic acid treated cells. Importantly, neurotoxin-induced release of cytochrome c levels as well as caspase activation was also inhibited in clavulanic acid treated cells. In addition, Bcl-xl levels were also restored and the Bcl-xl/Bax ratio that is critical for inducing apoptosis was increased in clavulanic acid treated cells. Overall, these results suggest that clavulanic acid is intimately involved in inhibiting neurotoxin-induced loss of mitochondrial function and induction of apoptosis that contributes towards neuronal survival.